JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline
Jazz Pharmaceuticals plans to expand indications for two oncology drugs, namely zanidatamab and Zepzelca.
Corporate Governance
Study finds restrictive clinical trial criteria excludes Lyme disease patients
Percheron plans to broaden pipeline following avicursen disappointment
Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst
APAC leading in Parkinson’s disease clinical trials
Generative AI has ‘potential to revolutionise clinical development’
‘Major milestone’ for UK clinical trials as new framework laid in parliament
UK desirability has turned a corner in clinical trials
